The estimated Net Worth of Eugene Durenard is at least $1.19 Milion dollars as of 13 January 2021. Eugene Durenard owns over 10,500 units of Co-Diagnostics Inc stock worth over $2,520 and over the last 5 years he sold CODX stock worth over $1,144,865. In addition, he makes $45,250 as Independent Director at Co-Diagnostics Inc.
Eugene has made over 6 trades of the Co-Diagnostics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,000 units of CODX stock worth $20,920 on 8 September 2021.
The largest trade he's ever made was selling 50,000 units of Co-Diagnostics Inc stock on 20 May 2020 worth over $916,500. On average, Eugene trades about 7,361 units every 26 days since 2019. As of 13 January 2021 he still owns at least 2,000 units of Co-Diagnostics Inc stock.
You can see the complete history of Eugene Durenard stock trades at the bottom of the page.
Dr. Eugene Durenard serves as Independent Director of the Company. Dr. Durenard is the Founder and CEO of Hyperbolic Holdings, a Swiss-based holding, management consulting and investment advisory company specialized in healthcare since February 2018. He is co-Founder and CIO of Healthcare Impact Holdings, an investment fund specialized in later-stage healthcare private ventures since May 2018. He is co-Founder and Trustee of Healthcare Impact Foundation, a charitable organization designed to sustainably fund the translation of innovation in life sciences since September 2017. He is co-Founder of Global Better Health, a platform designed to provide scientifically-based corporate wellness and preventive programs since December 2018. He is an advisor to and Managing Director of the Stetson Family Office since September 2016. Dr. Durenard brings a thorough multi-asset class investment and entrepreneurial experience spanning 20 years to the Board of Directors. He received his Ph.D. in Mathematics at Harvard in 1995 before beginning his career with Salomon Brothers in London.
As the Independent Director of Co-Diagnostics Inc, the total compensation of Eugene Durenard at Co-Diagnostics Inc is $45,250. There are 6 executives at Co-Diagnostics Inc getting paid more, with Dwight H. Egan having the highest compensation of $676,875.
Eugene Durenard is 50, he's been the Independent Director of Co-Diagnostics Inc since 2019. There are 6 older and 3 younger executives at Co-Diagnostics Inc. The oldest executive at Co-Diagnostics Inc is Richard Serbin, 75, who is the Independent Director.
Eugene's mailing address filed with the SEC is 2401 S. FOOTHILL DRIVE SUITE D, , SALT LAKE CITY, UT, 84109.
Over the last 7 years, insiders at Co-Diagnostics Inc have traded over $2,459,090 worth of Co-Diagnostics Inc stock and bought 8,205 units worth $11,819,010 . The most active insiders traders include Reed L Benson, James B Nelson oraz Dwight H Egan. On average, Co-Diagnostics Inc executives and independent directors trade stock every 79 days with the average trade being worth of $38,652. The most recent stock trade was executed by Brian Lee Brown on 20 March 2023, trading 3,000 units of CODX stock currently worth $5,700.
co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are
Co-Diagnostics Inc executives and other stock owners filed with the SEC include: